Abstract
The intricate interplay between circulating metabolites and immune responses, though crucial to disease pathophysiology, remains poorly understood and underexplored in systematic research. Here, we performed a comprehensive analysis of the immune response and circulating metabolome in two Western European cohorts (534 and 324 healthy individuals) and one from sub-Saharan Africa (323 healthy donors). At metabolic level, our analysis uncovered sex differences in the correlation between phosphatidylcholine and cytokine responses upon ex-vivo stimulations. Notably, sphingomyelin showed a significant negative correlation with the monocyte-derived cytokine production in response to Staphylococcus aureus stimulation, a finding validated through functional experiments. Subsequently, employing Mendelian randomization analysis, we established a link between sphingomyelin and COVID-19 severity, providing compelling evidence for a modulatory effect of sphingomyelin on immune responses during human infection. Collectively, our results represent a unique resource (https://lab-li.ciim-hannover.de/apps/imetabomap/) for exploring metabolic signatures associated with immune function in different populations, highlighting sphingomyelin metabolism as a potential target in treating inflammatory and infectious diseases.
Competing Interest Statement
M.G.N. and L.A.B.J. are scientific founders of TTxD and Lemba Therapeutics. M.G.N. is a founder of BioTRIP.
Funding Statement
This work was supported with funds provided by ERC starting grant 948207. I ASPASIA and Radboud University Medical Center Hypatia grant to Y.L. ERC advanced grant 833247 and Spinoza grant of the Netherlands Organization for Scientific research to M.G.N. and Helmholtz Initiative and Networking Fund to C.J.X. (1800167). This study was also supported by the COFONI (COVID19 Research Network of the State of Lower Saxony) with funding from the Ministry of Science and Culture of Lower Saxony, Germany (14764031843) and the Deutsche Forschungsgemeinschaft (DFG; German Research Foundation) under Germany Excellence Strategy EXC 2155 project number 390874280 to Y.L. The study received financial support from the Joint Programming Initiative, A Healthy Diet for a Healthy Life (JPI HDHL), and ZonMw (the Netherlands Organization for Health Research and Development), within the framework of the TransMic and TransInf projects.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Cohort_EU1: Originates from the Human Functional Genomics Project (500FG cohort), comprising 534 healthy individuals of Western European ancestry. More detailed information is available in prior publications (DOI: 10.1016/j.cell.2016.10.017). Cohort_EU2: Consists of 324 healthy Western European volunteers from the 300BCG cohort. Participants were recruited between April 2017 and June 2018. Further details are provided in related publications (DOI: 10.1172/JCI133935). Cohort_AF: Includes 323 healthy Tanzanian individuals recruited through the Kilimanjaro Christian Medical Center and Lucy Lameck Research Center. Recruitment occurred from March to December 2017. More details can be found in previous studies (DOI: 10.1038/s41590-021-00867-8). These datasets are fully open and publicly available, and no special application, screening, or registration was required to access them. Our results collectively represent a resource for exploring metabolic signatures associated with immune function (https://lab-li.ciim-hannover.de/apps/imetabomap/).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
